June 23, 2017
MADRID — Belimumab plus standard therapy was safe and effective over 10 years in patients with lupus, according to findings presented at the EULAR Annual Congress.
“In lupus, the underlying disease is always present and symptoms can erupt, or flare, without warning, making it incredibly difficult to manage everyday life,” David Roth, MD, MSCE, , R&D Immuno-Inflammation at , said in a company release. “Unlike most treatments used for [systemic lupus erythematosus SLE, belimumab has a specific mode of action that targets the underlying disease process. It has consistently proven its effectiveness, with four successful pivotal trials in SLE and data now shows that the disease control is sustained, helping to stabilize day-to-day symptoms and improve outcomes for patients in the longer-term.”